Subscribe
VBCR - August 2015, Volume 4, No 4 - Psoriatic Arthritis
Rosemary Frei, MSc

A study presented at the 2015 annual meeting of the International Society for Pharmaco­economics and Outcomes Research documented the steep risk in cost of treatment of psoriatic arthritis (PsA) with biologics.

The poster was also presented at the Academy of Managed Care Pharmacy conference in San Diego in early April.

The product made by the study’s sponsor, Celgene Corporation, to treat PsA is apremilast (Otezla). The phosphodiesterase 4 inhibitor is significantly less expensive than any of the large-molecule biologics. Value-Based Care in Rheumatology asked lead investigator Andreas Kuznik, PhD, whether combining this with the information in the poster could mean patients taking apremilast would have significantly lower annual PsA-related drug costs.

“That’s exactly right. Our product is priced at a significant discount relative to biologic products, and one would expect PsA-related costs to payers to be lower. We are actually evaluating this exact question right now in the same data set, but we have not yet disseminated these findings, so I am not able to share those results with you [yet],” responded Kuznik, Director of Global Pricing and Market Access at Celgene in Warren, NJ, via email.

Kuznik and 2 other researchers from Celgene extracted data from MarketScan databases regarding adults who had been diagnosed with PsA and who had a healthcare-plan claim for their first biologic between July 1, 2008, and July 31, 2013. Among the 25,565 patients included in the analysis, average per-patient total all-cause healthcare costs increased from $26,981 in 2008 to $41,317 in 2013.

At the same time, average PsA-related healthcare costs rose from $18,344 to $30,021 and PsA-related drug costs increased from $16,919 to $28,019.

Reference

Kuznik A, Eslava S, Cai J. Recent cost trends among patients using biologic agents for the treatment of psoriatic arthritis. In: Proceedings from the ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA. Abstract PMS29.

Related Items
Effect of Previous Biologic Use on Persistence of Tumor Necrosis Factor Inhibitor Treatment
Erin S. Fenner
VBCR - June 2017, Vol 6, No 2 published on June 29, 2017 in Psoriatic Arthritis
Bimekizumab, an IL-17A and IL-17F Inhibitor, Produces High Responses in Skin and Joints in Patients with Psoriatic Arthritis
Walter Alexander
VBCR - August 2016, Vol 5, No 4 published on August 25, 2016 in Psoriatic Arthritis
Ixekizumab Forges Ahead in Psoriatic Arthritis
Alice Goodman
VBCR - August 2016, Vol 5, No 4 published on August 25, 2016 in Psoriatic Arthritis
IL-6 Inhibitor Shows Promise in Patients with PsA
Phoebe Starr
VBCR - June 2016, Vol 5, No 3 published on July 7, 2016 in Psoriatic Arthritis
Poor Pregnancy Outcomes Seen in Women with Childhood-Onset SLE
Rosemary Frei, MSc
VBCR - April 2016, Vol 5, No 2 published on May 23, 2016 in Canadian Rheumatology Association Annual Meeting
Addressing Undertreatment of Patients with Gout Using EMR Data
Rosemary Frei, MSc
VBCR - April 2016, Vol 5, No 2 published on May 11, 2016 in Canadian Rheumatology Association Annual Meeting
Six-Month OBSErve Study Results Indicate Positive Effects of Belimumab in SLE
Rosemary Frei, MSc
VBCR - April 2016, Vol 5, No 2 published on May 8, 2016 in Canadian Rheumatology Association Annual Meeting
Improvements Needed in Access to Timely Quality Care
Rosemary Frei, MSc
VBCR - April 2016, Vol 5, No 2 published on May 7, 2016 in Canadian Rheumatology Association Annual Meeting
Orthotics Reduce Foot Pain in Juvenile Idiopathic Arthritis
Rosemary Frei, MSc
VBCR - April 2016, Vol 5, No 2 published on May 4, 2016 in Juvenile Idiopathic Arthritis
Long-Term Benefits Seen in Patients with Psoriatic Arthritis Taking Golimumab
Alice Goodman
VBCR - February 2016, Vol 5, No 1 published on March 15, 2016 in Psoriatic Arthritis
Last modified: August 26, 2015
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology